Assistant Director of Health Espen Nakstad says it is good news that the EU Medicines Agency has approved Johnson & Johnson’s corona vaccine.
On Thursday, the Johnson & Johnson vaccine became the fourth to be approved in the EU. It is administered in just one dose, and, according to clinical tests, it is up to 72% effective.
“It is good news that Johnson & Johnson received temporary approval for use in the EU. It will help us in Norway as well,” Nakstad told news bureau NTB.
The EU has already approved the vaccines from Pfizer / BioNTech, Moderna, and AstraZeneca. These are already in use in Norway, although the use of the AstraZeneca vaccine has now been suspended until it has been clarified whether it can lead to serious side effects.
FHI pleased
The Norwegian Institute of Public Health (FHI) is also pleased that the EU approved the Johnson & Johnson vaccine. However, it does not know when Norway can expect the first vaccine doses.
A total of 900,000 doses are planned for the second quarter, but if these come too late, it could have consequences for the Norwegian vaccine plans.
“We know very little about the delivery plans from Johnson & Johnson. We are happy that it has been approved, as we have a fourth vaccine in the European market,” chief physician Are Stuwitz Berg at the FHI told NTB.
Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews
Do you have a news tip for Norway Today? We want to hear it. Get in touch at [email protected]
Be the first to comment on "Nakstad: Johnson & Johnson corona vaccine will help Norway"